Recent evidence suggests that expression of CD34 on the cell membrane does not always correlate with stem cell activity. In the mouse, there is a highly quiescent population of stem cells that lacks CD34 expression, but has full reconstituting capacity. The current review addresses the discovery of a similar population of dormant CD34-negative human hematopoietic stem cells. This information casts some uncertainty on the benefits of CD34 + cell isolation for stem cell transplantation, until more is known about the novel CD34-negative stem cell population. Methods designed to achieve removal of specific mature blood cell lineages might prove to be most advantageous in the future. Leukemia (2000) 14, 773-776.
The cell surface protein CD34 is frequently used as a marker for positive selection of engrafting human hematopoietic stem and progenitor cells, both in research and in clinical transplantation. Many successful transplantations have been done with CD34-enriched cells, and the patients have engrafted rapidly and continue to do well years later. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The benefits of CD34-positive cell selection are that tumor or leukemic cells that lack CD34 expression can be largely removed from the transplant inoculum, mature T lymphocytes that are likely to give rise to graft-versus-host disease can be depleted several logs, and the transplant inoculum can be debulked by removal of mature cells prior to ex vivo transduction for gene therapy applications. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] A sense of uncertainty as to whether selection of cells expressing CD34 for transplantation might be excluding another population of primitve stem cells that were devoid of CD34 expression first arose in 1996. In that year, Osawa and colleagues published a study which defined a murine CD34-negative cell which had full engrafting capacity. 11 While extremely thought provoking and interesting, this study was done in mice, and the correlation between murine and human CD34 had not been established.
The first evidence that there was a human correlate to the engrafting CD34 − murine stem cell was published by Bhatia et al, in 1998 . 12 In an elegant study using transplantation of highly selected human hematopoietic cell populations into immune deficient NOD/SCID mice, this team of investigators demonstrated that there was a low level of engraftment and hematopoietic capacity in human CD34 − cells. While this was a very well done and interesting study, the CD34 − cells with engrafting capacity were extremely rare, and the levels of engraftment in the NOD/SCID mice were very low; much lower than what could be obtained using equivalent numbers of cells from the CD34 + population. The relationship between CD34-positive and negative populations was still not clear, but definitely warranted further study. 15 had reported that the SP cells isolated from murine bone marrrow, which excluded the most Hoechst dye, were actually devoid of expression of CD34 at the cell surface, and had a significant capacity for hematopoietic reconstitution with generation of CD34 + cells. 15 The SP cells were present at low numbers, and the engraftment of the human SP CD34
− fraction in immune deficient mice had not yet been studied, at that point. Therefore, while the SP papers provoked much excitement and discussion, most transplanters of CD34 + cells were not yet worried that they might be excluding a valuable population in the sorting effort.
These worries began to surface when a very definitive paper explaining more of the biology of the CD34
− vs CD34 + cell populations was recently published. 16 This study, by Ogawa's laboratory, demonstrated that murine CD34
− stem cells could be induced to express CD34, and to increase engraftment capacity, following in vivo treatment of the mice with 5-fluorouracil. Sato et al hypothesized that the CD34 − stem cells exist in an extremely quiescent state, and that activation is required to cause upregulation of CD34 expression and induction into a state that is more readily able to engraft a recipient mouse. In the studies by their group, that activation was promoted by in vivo treatment of donor mice with 5-FU.
The 'activation' to which Ogawa and colleagues refer is not likely to be simply cell cycle induction, which could be induced by recruiting primitive hematopoietic stem cells into cycle to reconstitute hematopoiesis in a 5-FU-treated animal. Human hematopoietic cells can be identified that express high levels of CD34, yet are very highly quiescent, 17, 18 cannot be readily induced into cell cycle by cytokines, 17, 19, 20 and lack expression of the marker Ki67, indicating that they are in the G 0 phase of the cell cycle. [21] [22] [23] Our laboratory has recently demonstrated that the highly quiescent human CD34 + cells can be induced into cycle by reduction of cyclin dependent kinase inhibitors, 23 but there were no commensurate alterations in the levels of CD34 expression as the cells entered cycle (Dao and Nolta, unpublished data). The putative 'activa-ting' factors regulating induction of CD34 expression in Ogawa's 5-FU-treated mice remain unknown at the current time.
Krause et al, 24, 25 at Yale University, have extensively characterized the murine CD34 promoter, and are determining which transcription factors act as positive and negative regulators. These types of studies will give us clues as to which signaling pathways can induce CD34 expression. Other interesting studies have come from Fackler et al, 26 at John Hopkins Medical School, who demonstrated that phosphorylation of pre-formed CD34 protein would determine whether it was expressed on the cell surface or retained inside the cell. These studies show the importance of not relying on FACS data for cell surface CD34 expression to determine whether populations are truly CD34
+ vs CD34 − . Analyses to assess levels of CD34 mRNA and intracellular protein should also be done to determine whether CD34 is present, but not yet localized to the cell surface. An important point, however, is that cells that have CD34 mRNA and intracellular CD34 protein, but lack cell surface expression, will not be acquired for transplantation in a 'positive CD34 selection' device. So far, the selection devices to isolate CD34 + cells have not been highly efficient, with reported levels averaging 40 to 75% CD34 + cells in the end product that is transfused into patients. Therefore the likelihood that 'contaminating' CD34 − cells have been included in the transplantations done to date is high. However, there is a trend towards attempting to increase the purity of the end product, so the importance of inclusion of the CD34 − stem cell should be addressed. An interesting observation has been made regarding human CD34 expression, or the lack thereof, in our laboratory. Using the bnx/hu xenograft model, in which human hematopoiesis can be studied for 18 months, [27] [28] [29] [30] [31] [32] [33] we found that there are human cells with extensive colony-forming and long-term culture-initiating cell capacity that are recovered from the bone marrow of long-term engrafted animals ( Figure 1 ). These cells are absolutely devoid of expression of CD34 at the cell surface when isolated from the mice (Dao and Nolta, unpublished data). We are currently in the process of determining whether the cells contain intracellular CD34 protein, or CD34 message, and whether these cells have repopulating capacity in secondary transplantation studies. In line with our obser-
Figure 1 Human CD45
+ cells recovered from the bone marrow of long-term engrafted bnx mice lack expression of cell surface CD34, but retain significant regenerative capacity. + and CD34 − cells may also be 'interconvertible' is discussed by Goodell in a thought-provoking introduction to the Sato paper. 34 Using another long-term xenograft model, the pre-immune fetal sheep system, Zanjani and colleagues 35, 36 demonstrated that human CD34 − populations could account for all of the results reported, especially since the engraftment levels reported to that point were very low (Blood 1999; 94; 30a). They obtained very low levels of engraftment when highly purified CD34 − /lin − populations were transplanted. However, a definitive report by Nakamura et al, 37 described below, demonstrated that freshly isolated human CD34 − cells do have very low engraftment capacity, as measured in the NOD/SCID xenograft system, but will generate CD34 + stem cells with improved engraftment capacity following in vitro culture.
Nakamura et al 37 demonstrated that a relationship between the CD34 − and CD34 + stem cells similar to what Sato et al 16 described in the mouse also exists in man. They showed that highly purified human CD34 − , lineage − cells cultured with cytokines for 7 days on the murine stromal cell line HESS-5 expanded and upregulated expression of CD34. 37 This study represents the first definitive in vitro analysis of induction of CD34 expression from a CD34 − population in human cells. The expanded CD34
+ cells had CFU, LTCIC, and NOD/SCID mouse engrafting capacity. The human cell engraftment in the immune deficient mice was multilineage, although T lymphocyte development cannot be determined in NOD/SCID mice. Our laboratory is in the process of characterizing the potential for T lymphocyte development from CD34 − cells into NOD/SCID mice, as shown in the study by Bhatia et al. 12 Fujisaki et al 38 , and 'CD34-induced' human hematopoietic stem cells will determine whether the difference in reconstitution capacity lies at the level of homing, survival or expansion (Figure 2) .
After seeing the study by Nakamura et al, 37 the majority of our colleagues were convinced that there is a pre-CD34 + cell which should at least be considered for inclusion in bone marrow transplantation. + cells, and have longer or more durable reconstitution capacity, as suggested by the recent work from Zanjani and Verfaillie's laboratories, they should not be excluded from clinical transplantation.
The studies described in the current review have changed the sentiment of the hematopoiesis community from one of mild interest in this supposed 'other stem cell' to intense curiosity, and are causing repetition of the questions, 'which stem cell(s) should we be transplanting?', and 'to select or not to select?' At the present time, it seems most prudent to study and develop methods that will deplete mature, lineage-positive cells, while preserving uncommitted human hematopoietic stem cells that do and do not express CD34. Methods exist to isolate these uncommitted cells for research, including AC133 selection systems from Miltenyi Biotech (Auburn, CA, USA), and Stem Sep Columns for depletion of lineage-positive cells from Stem Cell Technologies (Vancouver, BC). Hopefully we will soon see these systems obtaining approval for use in clinical transplantation. 
